摘要
目的 探讨维拉帕米在经桡动脉心脏介入治疗中的应用及安全性。方法 60例经桡 动脉心脏介入治疗的患者,从桡动脉局部注入维拉帕米5 mg,观察注入前、后心率、血压、局部和全身 的变化及术中是否出现桡动脉痉挛。结果 60例患者注药前后心率、收缩压、舒张压均有一定程度 变化,但无显著性差异,术中未出现桡动脉痉挛,无心衰和新的房室传导阻滞出现。结论 在经桡动 脉心脏介入治疗时,局部注入维拉帕米5 mg,可预防桡动脉痉挛,且无明显副作用,安全有效。
Objective The objective of this study was to evaluate the security of verapamil in transradial catheterizati procedures. Method 60 patients submitted to a transradial cardiac catheterization were assigned to receive 5 mg of verapamil after sheath insertion. To investigate the heart rate, blood pressure, region and whole reaction at pre-and after-inject verapamil, whether radial artery spasm occurs during the transradial approach for coronary catheterization. Results the heart rate, blood pressure, region and whole reaction at pre-and after-inject verapamil have various changes but have no significant difference. And no radial artery spasm, congestive heart failure and new atrial ventricular block occur during the transradial approach for coronary catheterization. Conclusions Use 5 mg verapamil in transradial catheterizati procedures is safety and efficiency, which can prevent radial artery spasm occurs, and no significant adverse reaction.
出处
《中国分子心脏病学杂志》
CAS
2005年第6期790-791,共2页
Molecular Cardiology of China
